Investor Intelligence Report
ARMA SPORT
Overall Investability Score
74
/ 100
Strong Conviction Opportunity
ARMA presents a compelling pre-seed thesis: differentiated product, early institutional validation (NFL Seahawks LOI), and a massive addressable market. Key risks center on manufacturing scalability and clinical claim substantiation — common at this stage and manageable with proper capital deployment.
Dimension Breakdown
SCORE: 0–49 PASS · 50–69 WATCH · 70–84 CONVICTION · 85+ EXCEPTIONAL
— Dimension Analysis
92
Market Opportunity
$12B global sports glove market with clear adjacent expansion paths: football ($2.5B), baseball ($5B), golf ($500M), BMX ($1.2B), off-field fashion ($8B). Total accessible market is credible and large.
Multiple sport verticals identified with market sizing
Fashion/lifestyle crossover dramatically expands TAM
No true custom-fit competitor at scale
Market sizing sources not cited in deck
80
Team & Advisors
Dual founder structure with athlete credibility. Advisory bench is legitimately exceptional — two former Nike Football leads (Marshall & Morscheck) with 20+ years category experience, plus NFL co-CDOs.
Nike Football veterans directly advising product
Griffin twins as NFL insiders = built-in distribution
Retail brand operator (Linda Heasley, The Limited/Lane Bryant) for scale
No clear manufacturing or supply chain operator on core team
78
Traction & Validation
3 years R&D with 200+ user trials and an NFL Seahawks LOI are meaningful proof points for pre-seed. $240K raised against $750K target is modest but shows early conviction.
NFL team LOI is a top-tier institutional signal
2x patent pending + trade secrets = IP protection
200+ user trials demonstrates product iteration
LOI ≠ contract; conversion to paid deal is critical next step
Clinical performance stats (15–20% grip increase) need sourcing
75
Product Innovation
Spray-on co-polymer fabrication over 3D-printed hand molds is genuinely novel. Four-layer material system (sticky-palm, functional lattice, base-layer, micro-flocking) at 0.8mm is technically ambitious.
Spray-on fabrication is a defensible process differentiator
iPhone-based scanning lowers consumer acquisition friction
Glove B (AI sensors, 2028) is far out — roadmap risk
Durability and washability data not addressed in deck
68
Business Model
Glove C ($135 e-comm) anchors the model with clean unit economics potential. Glove B adds recurring SaaS-style revenue ($20/mth) which is compelling. The $500+ Glove X and team/orthopedic plays layer margin nicely.
Tiered model spans mass market to ultra-premium
Recurring revenue component (Glove B) improves LTV
COGS for spray-on custom fabrication not addressed
Unit economics, margins, CAC not presented
2028–2031 roadmap creates long payback horizon
65
Financials & Ask
$750K raise at $5M pre-money valuation via SAFE with 20% discount is reasonable for the stage. However the deck lacks revenue projections, burn rate, and use-of-funds breakdown — critical for closing conviction investors.
$5M pre-money is defensible given IP + NFL LOI
$240K raised signals early momentum
No revenue projections or financial model presented
No use-of-funds breakdown for the $750K
No runway or burn rate visibility
— Investor Archetypes by Fit
Sports Tech & Athlete Performance Investors
🔥 Primary Fit
Firms like Courtside VC, Elysian Park, and Sport Innovation Hub specialize here. ARMA's NFL pedigree, Seahawks LOI, and athlete co-CDOs speak directly to this archetype's thesis. Likely the fastest path to term sheet.
96%
Consumer Brand & DTC Investors
🔥 Primary Fit
Investors backing premium DTC brands (think Forerunner Ventures, Coefficient Capital) will be drawn to the spray-on custom process, the aspirational brand voice, and the multi-sport market breadth. The off-field fashion wedge ($8B) is a major hook.
88%
Deep Tech / Advanced Materials Investors
⚡ Strong Fit
Firms focused on materials science and manufacturing innovation will see the co-polymer spray-on fabrication as a platform, not just a glove. However, they'll probe hard on IP durability, process repeatability, and manufacturing scale-up costs.
78%
Impact / Athlete Equity Investors
⚡ Strong Fit
The Motley Twins' athlete-founder story, the Griffin Twins' inclusivity mandate, and the eco-friendly reclaimable polymer angle align well with investors focused on equitable sports economies. Relatively underexplored angle that could unlock non-dilutive funding too.
74%
Fashion & Luxury Goods Investors
◎ Moderate Fit
The $8B off-field fashion opportunity and Glove X's bespoke retail experience (1-of-1 design) attract luxury-oriented investors. Fit improves significantly once retail experience is live and brand positioning is proven at scale.
61%
Healthcare / Orthopedic Tech Investors
◎ Moderate Fit
Glove O's injury prevention & recovery angle targets sports medicine and orthopedic investors. Currently underbuilt in the deck — needs clinical data, rehab protocol partnerships, and insurance/team trainer distribution strategy to fully unlock this archetype.
55%
— Key Risk Register
Investment Risk Assessment
Manufacturing Scalability
High
Custom spray-on fabrication per athlete is inherently low-volume. Path to scaling throughput without sacrificing fit quality is the central operational question investors will probe.
Clinical Claim Substantiation
High
15–20% grip strength and 25–35% endurance claims appear throughout the deck but no study methodology, sample size, or third-party validation is referenced. Regulatory exposure if marketed as medical claims.
LOI to Revenue Conversion
Medium
NFL Seahawks LOI is a powerful signal but LOIs are non-binding. Failure to convert to a paid partnership would significantly damage credibility with follow-on investors.
Unit Economics Visibility
Medium
COGS for a custom-fabricated glove using proprietary spray technology is unknown from the deck. Margins at $135 (Glove C) could be very thin at low volumes.
Competitive Response
Medium
Nike, Under Armour, and Cutters have significant R&D budgets. Once the spray-on category proves out, a well-capitalized incumbent response is likely within 3–5 years.
Roadmap Execution Timeline
Low-Med
Gloves B, O, and X extend to 2028–2031. Investor patience for a 5-year product roadmap at pre-seed is realistic only if Glove C achieves strong early commercial traction.